Nanoparticle delivery of chemotherapy combination regimen improves the therapeutic efficacy in mouse models of lung cancer
Open accessAbstract
The combination chemotherapy regimen of cisplatin (CP) and docetaxel (DTX) is effective against a variety of cancers. However, combination therapies present unique challenges that can complicate clinical application, such as increases in toxicity and imprecise exposure of tumors to specific drug ratios that can produce treatment resistance. Drug co-encapsulation within a single nanoparticle (NP) formulation can overcome these challenges and further improve combinations' therapeutic index. In this report, we employ a CP prodrug (CPP) strategy to formulate poly(lactic-co-glycolic acid)-poly(ethylene glycol) (PLGA-PEG) NPs carrying both CPP and DTX. The dually loaded NPs display differences in drug release kinetics and in vitro cytotoxicity based on the structure of the chosen CPP. Furthermore, NPs containing both drugs showed a significant improvement in treatment efficacy versus the free drug combination in vivo.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Several preclinical formulations of multiple drugs co-loaded into various nanoparticle carriers have been evaluated and shown some promise for cancer treatment.
“Moreover, several preclinical formulations of multiple drugs co-loaded into various nanoparticle carriers have also been evaluated and shown some promise for the treatment of cancers [9, 10].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
PLGA-based nanoparticles: An overview of biomedical applications
Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Breton, A. L., & Véronique Préat, A. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.043 · Cited by 3,884 · see citing works
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,953 · see citing works
Mechanisms of Cisplatin Nephrotoxicity
Miller, R. P., Tadagavadi, R. K., Ramesh, G., & Reeves, W. B. (2010) · Toxins · doi:10.3390/toxins2112490 · Cited by 1,635 · see citing works
Barua, S., & Mitragotri, S. (2014) · Nano Today · doi:10.1016/j.nantod.2014.04.008 · Cited by 1,270 · see citing works
Dhar, S., Gu, F., Langer, R., Farokhzad, O. C., & Lippard, S. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809154105 · Cited by 994 · see citing works
Mechanisms of drug combinations: interaction and network perspectives
Jia, J., Zhu, F., Ma, X., Cao, Z., Li, Y. X., & Chen, Y. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2683 · Cited by 975 · see citing works
Synergistic drug combinations tend to improve therapeutically relevant selectivity
Lehár, J., Krueger, A., Avery, W., Heilbut, A. M., Johansen, L. M., Price, E. R., Rickles, R. J., Short, G. F., Staunton, J. E., Jin, X., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1549 · Cited by 941 · see citing works
Nanoparticle-based combination therapy toward overcoming drug resistance in cancer
Hu, C. J., & Zhang, L. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.008 · Cited by 688 · see citing works
Kolishetti, N., Dhar, S., Valencia, P. M., Lin, L. Q., Karnik, R., Lippard, S. J., Langer, R., & Farokhzad, O. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011368107 · Cited by 563 · see citing works
Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery
Zheng, Y., Suntharalingam, K., Johnstone, T. C., Yoo, H., Wei, L., Brooks, J. G., & Lippard, S. J. (2014) · Journal of the American Chemical Society · doi:10.1021/ja5038269 · Cited by 441 · see citing works
Recognition and processing of cisplatin- and oxaliplatin-DNA adducts
Chaney, S. G., Campbell, S. L., Bassett, E., & Wu, Y. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.08.008 · Cited by 395 · see citing works
Nanoparticles for combination drug therapy
Ma, L., Kohli, M., & Smith, A. (2013) · ACS Nano · doi:10.1021/nn405674m · Cited by 367 · see citing works
Liao, L., Liu, J., Dreaden, E. C., Morton, S. W., Shopsowitz, K. E., Hammond, P. T., & Johnson, J. A. (2014) · Journal of the American Chemical Society · doi:10.1021/ja502011g · Cited by 365 · see citing works
PEGylated PLGA nanoparticles for the improved delivery of doxorubicin
Park, J. Y., Fong, P., Lu, J., Russell, K. S., Booth, C. J., Saltzman, W. M., & Fahmy, T. M. (2009) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2009.02.002 · Cited by 339 · see citing works
Lancet, J. E., Cortes, J. E., Hogge, D. E., Tallman, M. S., Kovacsovics, T. J., Damon, L. E., Komrokji, R. S., Solomon, S. R., Kolitz, J. E., Cooper, M. A., et al. (2014) · Blood · doi:10.1182/blood-2013-12-540971 · Cited by 339 · see citing works
Docetaxel (Taxotere®)-cisplatin (TC): An effective drug combination in gastric carcinoma
Roth, A., Maibach, R. C., Martinelli, G., et al. (2000) · Annals of Oncology · doi:10.1023/a:1008342013224 · Cited by 207 · see citing works
Miao, L., Guo, S., Zhang, J., Kim, W. Y., & Huang, L. (2014) · Advanced Functional Materials · doi:10.1002/adfm.201401076 · Cited by 178 · see citing works
Guo, S., Lin, C. M., Xu, Z., Miao, L., Wang, Y., & Huang, L. (2014) · ACS Nano · doi:10.1021/nn5010815 · Cited by 164 · see citing works
Hall, M. D., Dillon, C. T., Zhang, M., Beale, P. J., Cai, Z., Lai, B. C. H., Stampfl, A. P. J., & Hambley, T. W. (2003) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-003-0471-6 · Cited by 157 · see citing works
Opportunities and Challenges in the Development of Experimental Drug Combinations for Cancer
Humphrey, R. W., Brockway-Lunardi, L., Bonk, D., Dohoney, K. M., Doroshow, J. H., Meech, S. J., Ratain, M. J., Topalian, S. L., & Pardoll, D. M. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr246 · Cited by 135 · see citing works
Georgoulias, V., Ardavanis, A. S., Agelidou, A., Agelidou, M., Chandrinos, V., Tsaroucha, E., Toumbis, M., Kouroussis, C., Syrigos, K., Polyzos, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.004 · Cited by 134 · see citing works
Effect of drug release kinetics on nanoparticle therapeutic efficacy and toxicity
Sethi, M., Sukumar, R., Karve, S., Werner, M. E., Wang, E. C., Moore, D. T., Kowalczyk, S. R., Zhang, L., & Wang, A. Z. (2014) · Nanoscale · doi:10.1039/c3nr05961h · Cited by 102 · see citing works
Self-citationAu, K. M., Min, Y., Tian, X., Zhang, L., Perello, V., Caster, J. M., & Wang, A. Z. (2015) · ACS Nano · doi:10.1021/acsnano.5b02913 · Cited by 84 · see citing works
Self-citationVasey, P. A., Paul, J., Birt, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2069 · Cited by 74 · see citing works
Dimopoulos, M. A., Bakoyannis, C., Georgoulias, V., et al. (1999) · Annals of Oncology · doi:10.1023/a:1008379500436 · Cited by 67 · see citing works
The Effect of Ligand Lipophilicity on the Nanoparticle Encapsulation of Pt(IV) Prodrugs
Johnstone, T. C., & Lippard, S. J. (2013) · Inorganic Chemistry · doi:10.1021/ic4010642 · Cited by 60 · see citing works
Miller, V. A., & Kris, M. G. (2000) · PubMed · Cited by 28 · see citing works
Erratum: The Systems Biology Graphical Notation
Novère, N. L., Hucka, M., Mi, H., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt0909-864d · Cited by 22 · see citing works
Erratum: Synergistic drug combinations tend to improve therapeutically relevant selectivity
Lehár, J., Krueger, A. S., Avery, W., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt0909-864c · Cited by 21 · see citing works
Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
Raut, L. S. (2015) · South Asian Journal of Cancer · doi:10.4103/2278-330x.149950 · Cited by 18 · see citing works
Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer.
Chevalier, T. L., Bérille, J., Zalcberg, J. R., et al. (1999) · PubMed · Cited by 15 · see citing works
Park, S. H., Cho, E. K., Bang, S., et al. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-21 · Cited by 14 · see citing works
Khuri, F. R. (2002) · PubMed · Cited by 6 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Wan, X., Beaudoin, J. J., Vinod, N., Min, Y., Makita, N., Bludau, H., Jordan, R., Wang, A., Sokolsky, M., & Kabanov, A. V. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.032 · Cited by 201 · see citing works
Self-citationNanoformulations for combination or cascade anticancer therapy
Miao, L., Guo, S., Lin, C. M., Liu, Q., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.003 · Cited by 178 · see citing works
Wan, X., Min, Y., Bludau, H., Keith, A., Sheiko, S. S., Jordan, R., Wang, A. Z., Sokolsky-Papkov, M., & Kabanov, A. V. (2018) · ACS Nano · doi:10.1021/acsnano.7b07878 · Cited by 158 · see citing works
Self-citation
- Authors
- Tian, J., Min, Y., Rodgers, Z., Wan, X., Qiu, H., Mi, Y., Tian, X., Wagner, K. T., Caster, J. M., Qi, Y., Roche, K., Zhang, T., Cheng, J., & Wang, A. Z.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Duke Medical Center (US)
- University of Illinois Urbana-Champaign (US)
- Corresponding author
- Wang, Andrew Z.
- ORCID
- Venue
- Nanomedicine: Nanotechnology, Biology and Medicine
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 13
- Issue
- 3
- Pages
- 1301-1307
- ISSN
- 1549-9634 (ISSN-L)
- PMC
- PMC5392447
- OpenAlex
- W2551715345
- Cited by
- 25
- References
- 33
- Citations by year
- 2025: 1 · 2024: 4 · 2023: 2 · 2022: 2 · 2021: 4 · 2020: 2 · 2019: 4 · 2018: 3 · 2017: 3
- FWCI
- 1.36
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nanomedicine Nanotechnology Biology and Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Natural Science Foundation of Tianjin City (15JCYBJC21100)
- National Cancer Institute (U54CA198999, R01CA178748-01, R21 CA182322)
- National Institutes of Health
- Carolina Center of Cancer Nanotechnology Excellence, University of North Carolina - Chapel Hill
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- nanoparticle drug delivery, combination chemotherapy, cisplatin, docetaxel, cisplatin prodrug, PLGA-PEG nanoparticles, co-encapsulation, lung cancer, drug release kinetics, cytotoxicity, treatment efficacy, drug toxicity
- MeSH terms
- Docetaxel, Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Drug Carriers, Drug Combinations, Female, Humans, Lung, Lung Neoplasms, Mice, Nude, Polyethylene Glycols, Polyglactin 910, Prodrugs, Taxoids, Cell Line, Tumor, Mice, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
